On June 19, 2026, the Chief Health Officer of Victoria, Australia, issued a health alert documenting six cases of acute liver injury since January, all in patients who used unapproved products labeled “retatrutide” purchased online and through social media. Symptoms included fatigue, jaundice, abdominal pain, dark urine, and unusual bruising.
Read carefully
The alert states that toxicity may be related to a contaminant in the product rather than retatrutide itself, and that at the time of the alert, the contaminant had not been identified. So: six confirmed liver injuries, a suspected contaminant, and a chemical composition not yet disclosed.
Anyone using this as evidence that retatrutide damages the liver is overinterpreting. Anyone ignoring the alert because the contaminant was not named is underinterpreting.
Trial safety records describe the molecule
Retatrutide’s clinical trial safety record describes the molecule itself. In trials, 1% of participants had transient liver enzyme elevations more than three times normal, and mean liver enzyme levels remained unchanged or decreased at 48 weeks. No liver toxicity signal was found in trials.
Health alerts describe what is in the vial
Health alerts describe what is in an unverified vial. These are two very different things, and the health alert is what you are actually injecting. Gray-market products may contain contaminants, incorrect doses, or entirely different compounds.
Why the distinction matters
If you are waiting for retatrutide approval, the trial safety record is an important reference. If you are considering buying from the gray market, the health alert is the more direct warning. Understanding the difference between these two information sources helps make more rational judgments.
Conclusion
The six liver injury cases are real, but attributing them directly to the retatrutide molecule is not supported by current evidence. The contaminant suspicion remains unresolved, and the alert deserves serious attention without being overinterpreted.